NCT06796114 - Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

June 25, 2027

Study Completion Date

January 31, 2030

Conditions

Hepatocellular Carcinoma

Interventions

OTHER

blood sample

"A total of 48 ml of blood will be collected at baseline (before STRIDE initiation):~* 6 EDTA 6 ml tubes for PBMC collection~* 2 EDTA 6 ml tube for plasma collection"

Trial Locations (8)

Unknown

RECRUITING

CHU de Besançon, Besançon

NOT_YET_RECRUITING

CH de Chalon sur Saône, Chalon-sur-Saône

NOT_YET_RECRUITING

CHU Grenoble, Grenoble

NOT_YET_RECRUITING

CH de Mulhouse, Mulhouse

NOT_YET_RECRUITING

Hôpital Beaujon - APHP, Paris

NOT_YET_RECRUITING

Hôpital Henri Mondor - APHP, Paris

NOT_YET_RECRUITING

Hôpital La Pitié Salpêtrière - APHP, Paris

NOT_YET_RECRUITING

ICANS, Strasbourg